Do analysts rate CDIO or PLRZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, CDIO or PLRZ?

Polyrizon has lower revenue, but higher earnings than Cardio Diagnostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardio Diagnostics $10K 589.04 -$6.50M -$3.38 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Do analysts rate NEUP or CDIO?

Neuphoria Therapeutics currently has a consensus target price of $21.00, indicating a potential upside of 349.68%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Neuphoria Therapeutics is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate PLUR or CDIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PLUR or CDIO more profitable?

Pluri has a net margin of -2,162.08% compared to Cardio Diagnostics' net margin of -36,950.00%. Pluri's return on equity of 0.00% beat Cardio Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Pluri -2,162.08% N/A -106.59% Cardio Diagnostics -36,950.00% -78.82% -72.87%

Do analysts prefer DYAI or CDIO?

Dyadic International currently has a consensus target price of $3.00, suggesting a potential upside of 329.18%. Given Dyadic International's stronger consensus rating and higher probable upside, research analysts clearly believe Dyadic International is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Cardio Diagnostics (CDIO) Competitors

$1.99 +0.03 (+1.53%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$2.03 +0.04 (+2.01%)

As of 04:00 AM Eastern

Compare

CDIO vs. NRSN, PLRZ, NEUP, PLUR, and DYAI

Should you buy Cardio Diagnostics stock or one of its competitors? MarketBeat compares Cardio Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardio Diagnostics include NeuroSense Therapeutics (NRSN), Polyrizon (PLRZ), Neuphoria Therapeutics (NEUP), Pluri (PLUR), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry.

How does Cardio Diagnostics compare to NeuroSense Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Cardio Diagnostics has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Cardio Diagnostics	$10K	589.04	-$6.50M	-$3.38	N/A

NeuroSense Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. NeuroSense Therapeutics' return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 13.3% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NeuroSense Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the broader market.

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 1 mentions for NeuroSense Therapeutics and 0 mentions for Cardio Diagnostics. NeuroSense Therapeutics' average media sentiment score of 0.00 equaled Cardio Diagnostics'average media sentiment score.

Company	Overall Sentiment
NeuroSense Therapeutics	Neutral
Cardio Diagnostics	Neutral

NeuroSense Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 1,030.92%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe NeuroSense Therapeutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

NeuroSense Therapeutics beats Cardio Diagnostics on 10 of the 15 factors compared between the two stocks.

How does Cardio Diagnostics compare to Polyrizon?

Cardio Diagnostics (NASDAQ:CDIO) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Polyrizon has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. Polyrizon's return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%
Polyrizon	N/A	N/A	N/A

8.1% of Cardio Diagnostics shares are held by institutional investors. 13.3% of Cardio Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Polyrizon has lower revenue, but higher earnings than Cardio Diagnostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	589.04	-$6.50M	-$3.38	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

In the previous week, Polyrizon had 6 more articles in the media than Cardio Diagnostics. MarketBeat recorded 6 mentions for Polyrizon and 0 mentions for Cardio Diagnostics. Polyrizon's average media sentiment score of 0.66 beat Cardio Diagnostics' score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardio Diagnostics	Neutral
Polyrizon	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cardio Diagnostics has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.91, indicating that its share price is 291% less volatile than the broader market.

Summary

Polyrizon beats Cardio Diagnostics on 6 of the 10 factors compared between the two stocks.

How does Cardio Diagnostics compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Neuphoria Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market.

Neuphoria Therapeutics currently has a consensus target price of $21.00, indicating a potential upside of 349.68%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Neuphoria Therapeutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 1 mentions for Neuphoria Therapeutics and 0 mentions for Cardio Diagnostics. Neuphoria Therapeutics' average media sentiment score of 0.00 equaled Cardio Diagnostics'average media sentiment score.

Company	Overall Sentiment
Neuphoria Therapeutics	Neutral
Cardio Diagnostics	Neutral

Neuphoria Therapeutics has higher revenue and earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.61	-$370K	-$11.06	N/A
Cardio Diagnostics	$10K	589.04	-$6.50M	-$3.38	N/A

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 13.3% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Neuphoria Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. Neuphoria Therapeutics' return on equity of -76.93% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

Summary

Neuphoria Therapeutics beats Cardio Diagnostics on 11 of the 15 factors compared between the two stocks.

How does Cardio Diagnostics compare to Pluri?

Pluri (NASDAQ:PLUR) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

Pluri has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market.

Pluri has a net margin of -2,162.08% compared to Cardio Diagnostics' net margin of -36,950.00%. Pluri's return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

16.6% of Pluri shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 43.2% of Pluri shares are owned by insiders. Comparatively, 13.3% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Pluri had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 2 mentions for Pluri and 0 mentions for Cardio Diagnostics. Pluri's average media sentiment score of 0.35 beat Cardio Diagnostics' score of 0.00 indicating that Pluri is being referred to more favorably in the media.

Company	Overall Sentiment
Pluri	Neutral
Cardio Diagnostics	Neutral

Cardio Diagnostics has lower revenue, but higher earnings than Pluri. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	18.60	-$22.58M	-$4.53	N/A
Cardio Diagnostics	$10K	589.04	-$6.50M	-$3.38	N/A

Summary

Pluri beats Cardio Diagnostics on 8 of the 13 factors compared between the two stocks.

How does Cardio Diagnostics compare to Dyadic International?

Dyadic International (NASDAQ:DYAI) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Dyadic International has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the broader market.

Dyadic International has a net margin of -192.40% compared to Cardio Diagnostics' net margin of -36,950.00%. Cardio Diagnostics' return on equity of -78.82% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-192.40%	-1,005.45%	-77.64%
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by insiders. Comparatively, 13.3% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Dyadic International's average media sentiment score of 0.00 equaled Cardio Diagnostics'average media sentiment score.

Company	Overall Sentiment
Dyadic International	Neutral
Cardio Diagnostics	Neutral

Dyadic International currently has a consensus target price of $3.00, suggesting a potential upside of 329.18%. Given Dyadic International's stronger consensus rating and higher probable upside, research analysts clearly believe Dyadic International is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cardio Diagnostics has lower revenue, but higher earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	8.24	-$7.36M	-$0.23	N/A
Cardio Diagnostics	$10K	589.04	-$6.50M	-$3.38	N/A

Summary

Dyadic International beats Cardio Diagnostics on 8 of the 14 factors compared between the two stocks.

Get Cardio Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDIO vs. The Competition

Export

Metric	Cardio Diagnostics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.80M	$3.34B	$6.48B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.58%
P/E Ratio	-0.59	18.61	23.69	23.74
Price / Sales	589.04	299.45	514.83	109.27
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	0.52	8.04	10.43	6.78
Net Income	-$6.50M	$23.89M	$3.57B	$337.51M
7 Day Performance	-15.32%	-3.28%	0.27%	-2.34%
1 Month Performance	8.74%	2.78%	3.25%	1.88%
1 Year Performance	-58.88%	36.03%	22.24%	25.55%

Cardio Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDIO Cardio Diagnostics	0.7126 of 5 stars	$1.99 +1.5%	N/A	-58.2%	$5.80M	$10K	N/A	1	Gap Up
NRSN NeuroSense Therapeutics	2.4983 of 5 stars	$0.82 +2.5%	$8.50 +936.6%	-58.0%	$26.70M	N/A	N/A	10	Positive News
PLRZ Polyrizon	1.068 of 5 stars	$14.10 +0.1%	N/A	+159.5%	$26.37M	N/A	N/A	N/A	News Coverage Analyst Upgrade Gap Down
NEUP Neuphoria Therapeutics	2.8335 of 5 stars	$4.84 -1.0%	$21.00 +333.9%	-32.0%	$26.16M	-$13.27K	N/A	N/A	Positive News Gap Down
PLUR Pluri	1.0182 of 5 stars	$2.40 +1.3%	N/A	-50.4%	$25.90M	$1.08M	N/A	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDIO) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardio Diagnostics (CDIO) Competitors

CDIO vs. NRSN, PLRZ, NEUP, PLUR, and DYAI

How does Cardio Diagnostics compare to NeuroSense Therapeutics?

Summary

How does Cardio Diagnostics compare to Polyrizon?

Summary

How does Cardio Diagnostics compare to Neuphoria Therapeutics?

Summary

How does Cardio Diagnostics compare to Pluri?

Summary

How does Cardio Diagnostics compare to Dyadic International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardio Diagnostics (CDIO) Competitors

CDIO vs. NRSN, PLRZ, NEUP, PLUR, and DYAI

How does Cardio Diagnostics compare to NeuroSense Therapeutics?

Which has better earnings & valuation, NRSN or CDIO?

Is NRSN or CDIO more profitable?

Do institutionals and insiders hold more shares of NRSN or CDIO?

Which has more volatility and risk, NRSN or CDIO?

Does the media prefer NRSN or CDIO?

Do analysts recommend NRSN or CDIO?

Summary

How does Cardio Diagnostics compare to Polyrizon?

Is CDIO or PLRZ more profitable?

Do insiders & institutionals believe in CDIO or PLRZ?

Which has stronger valuation & earnings, CDIO or PLRZ?

Does the media favor CDIO or PLRZ?

Do analysts rate CDIO or PLRZ?

Which has more risk & volatility, CDIO or PLRZ?

Summary

How does Cardio Diagnostics compare to Neuphoria Therapeutics?

Which has more risk & volatility, NEUP or CDIO?

Do analysts rate NEUP or CDIO?

Does the media prefer NEUP or CDIO?

Which has better valuation & earnings, NEUP or CDIO?

Do insiders & institutionals have more ownership in NEUP or CDIO?

Is NEUP or CDIO more profitable?

Summary

How does Cardio Diagnostics compare to Pluri?

Which has more risk and volatility, PLUR or CDIO?

Is PLUR or CDIO more profitable?

Do insiders and institutionals hold more shares of PLUR or CDIO?

Do analysts rate PLUR or CDIO?

Does the media prefer PLUR or CDIO?

Which has preferable valuation & earnings, PLUR or CDIO?

Summary

How does Cardio Diagnostics compare to Dyadic International?

Which has more volatility and risk, DYAI or CDIO?

Is DYAI or CDIO more profitable?

Do insiders and institutionals hold more shares of DYAI or CDIO?

Does the media prefer DYAI or CDIO?

Do analysts prefer DYAI or CDIO?

Which has stronger valuation & earnings, DYAI or CDIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools